Management of Ibrutinib Toxicities: a Practical Guide
- 1 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Hematologic Malignancy Reports
- Vol. 15 (3), 177-186
- https://doi.org/10.1007/s11899-020-00576-3
Abstract
Purpose of Review Ibrutinib is a first-in-class, highly potent Bruton tyrosine kinase inhibitor which has become standard of care for patients with chronic lymphocytic leukaemia and other lymphoproliferative disorders. It requires indefinite administration which places emphasis on toxicity and long-term tolerance. Recent Findings Extensive use of ibrutinib in studies and clinical practice has better defined its full toxicity profile which has made its use more challenging than initially foreseen. In particular, dysrhythmias, bleeding, infections and constitutional symptoms have been reported and can result in dose reduction or discontinuation of ibrutinib. Herein, we review the common as well as rare but important toxicities and discuss approach and management on a practical level. We also highlight that patients should be regularly monitored for adverse events and proactively treated to minimise side effects and avoid disruption.This publication has 87 references indexed in Scilit:
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2015
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsBlood, 2015
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaThe New England Journal of Medicine, 2015
- Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapyBlood, 2015
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2014
- Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLBlood, 2014
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activityLeukemia, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood, 2012